Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a public biopharmaceutical company that is developing GP2, a novel peptide immunotherapy, and has commenced a Phase III clinical trial, called Flamingo-01. GP2 is derived from the HER2/neu protein. In a Phase IIb clinical trial in the HER2/neu positive adjuvant setting, no breast cancer recurrences were observed after median 5 years of follow-up. For the 146 patients who have been treated with GP2 immunotherapy to date over 4 clinical trials, treatment was well tolerated and no serious adverse events were observed related to the immunotherapy.